Apellis Pharmaceuticals, Inc. (APLS) Tops Q4 EPS by 85c

Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) reported Q4 EPS of $0.47, $0.85 better than the analyst estimate of ($0.38). Revenue for the quarter came in at $199.91 million versus the consensus estimate of $198.82 million.

For earnings history and earnings-related data on Apellis Pharmaceuticals, Inc. (APLS) click here.

You May Also Be Interested In

• Toll Brothers (TOL) Tops Q3 EPS by 5c, reaffirms guidance
• Prenetics Global (PRE) Tops Q2 EPS by 18c
• La-Z-Boy (LZB) Misses Q1 EPS by 6c, Misses on Revenue; Offers Weak Q2 Revenue Guidance